N6-Cyclopentyl-ATP

N6-Cyclopentyladenosine-5'-O-triphosphate, Sodium salt

Catálogo Nº Apresentação Preço (R$) Comprar
NU-878S 250 μl (10 mM)Sob demanda Adicionar ao Carrinho
NU-878L 5 x 250 μl (10 mM)Sob demanda Adicionar ao Carrinho
Structural formula of N6-Cyclopentyl-ATP (N6-Cyclopentyladenosine-5'-O-triphosphate, Sodium salt)
Structural formula of N6-Cyclopentyl-ATP

For general laboratory use.

Envio: shipped on gel packs

Condições de armazenamento: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Validade: 12 months after date of delivery

Fórmula molecular: C15H24N5O13P3 (free acid)

Peso molecular: 575.30 g/mol (free acid)

CAS#: 189822-11-5

Pureza: ≥ 95 % (HPLC)

Forma: solution in water

Concentração: 10 mM - 11 mM

pH: 7.5 ±0.5

Propriedades espectroscópicas: λmax 270 nm, ε 19.9 L mmol-1 cm-1 (Tris-HCl pH 7.5)

Formulários:
Agonistic ligand, mainly for nucleoside receptor A1, with less affinity to A2A and A3
Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands. In some cases nucleoside phosphates act also directly on nucleoside receptors.

Referências selecionadas:
Sirci et al. (2012) Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists. J. Comput. Aided Mol. Des. 26:1247.

Volonte et al. (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J. 276:318.

Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 1783:673.

Joshi et al. (2005) Purine derivatives as ligands for A3 adenosine receptors. Current Topics in Medicinal Chemistry 5:1275.

Hess (2001) Recent advantages in adenosine receptor antagonist research. Expert Opin. Ther. Patents 11 (10):1533.

Jacobson (2001) Probing adenosine and P2 receptors: design of novel purines and nonpurines as selective ligands. Drug Development Res. 52:178.

Jacobson et al. (2001) Ribose modified nucleosides and nucleotides as ligands for purine receptors. Nucleosides, Nucleotides & Nucleic Acids 20 (4):333.

Van Galen et al. (1994) A binding site model and structure-activity relationships for rat A3 adenosine receptor. Molecular Pharmacology 45:1101.